Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

Despite the promising result with FLT3 inhibitors in AML, the emergence of resistance poses a significant challenge, leading to a shorter response duration and inferior survival. This is frequently driven by on-target or parallel prosurvival mutations. The emergence of BCR–ABL1 as a mechanism of pos...

Full description

Bibliographic Details
Main Authors: Ahmad S. Alotaibi, Musa Yilmaz, Sanam Loghavi, Courtney DiNardo, Gautam Borthakur, Tapan M. Kadia, Beenu Thakral, Naveen Pemmaraju, Ghayas C. Issa, Marina Konopleva, Nicholas J. Short, Keyur Patel, Guilin Tang, Farhad Ravandi, Naval Daver
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
FLT3
BCR-ABL
FLT3 inhibitors
secondary mutations
AML
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.588876/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.588876/full

Similar Items